Bicara Cash and Securities Decrease to $414.8M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BCAX?
As of December 31, 2025, Bicara had cash, cash equivalents and marketable securities of $414.8M, compared to $489.7M in cash and cash equivalents as of December 31, 2024. "Bicara enters the year with exceptional momentum across our clinical, regulatory, and corporate priorities," said Claire Mazumdar, CEO at Bicara Therapeutics. "The continued advancement of our pivotal FORTIFI-HN01 study, the robust body of clinical data supporting ficerafusp alfa's differentiated profile, and the alternate dosing option for ficerafusp alfa all underscore the significant progress we've made toward transforming outcomes for patients with HPV-negative head and neck cancer. Coupled with our fortified financial position from our recent financing, we are well positioned to execute on our milestones, scale our organization for potential commercialization, if approved, and deliver meaningful value for patients and shareholders throughout the year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCAX
Wall Street analysts forecast BCAX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 19.040
Low
11.00
Averages
30.80
High
48.00
Current: 19.040
Low
11.00
Averages
30.80
High
48.00
About BCAX
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bicara Therapeutics Reports Q4 2025 Financial Results
- Financial Performance: Bicara Therapeutics reported a GAAP EPS of -$0.68 for Q4 2025, indicating challenges in profitability that may impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, Bicara had cash, cash equivalents, and marketable securities totaling $414.8 million, down from $489.7 million in 2024, reflecting pressure on the company's financial management and liquidity.
- Increased R&D Expenses: Research and development expenses rose to $33.0 million in Q4 2025 from $19.9 million in Q4 2024, primarily due to costs associated with ongoing pivotal Phase 2/3 clinical trials and increased personnel costs, highlighting the company's commitment to advancing its pipeline.
- Capital Raising: Bicara raised $161.8 million in net proceeds through an oversubscribed public offering in Q1 2026, bolstering its financial resources to support future R&D projects and clinical trials.
See More
BICARA THERAPEUTICS INC Reports Q4 Net Loss of $37.4 Million; FY2025 Net Loss Totals $138.0 Million
Financial Performance: Bicarat Therapeutics reported a net loss of $37.4 million for the fourth quarter.
Annual Projection: The company anticipates a net loss of $138.0 million for the fiscal year 2025.
See More
BICARA THERAPEUTICS BEGINS PHASE 3 OF FORTIFI-HN01 KEY TRIAL; INTERIM RESULTS ANTICIPATED BY MID-2027
Phase 3 Initiation: Bicarat Therapeutics has initiated Phase 3 of the Fortifi-HN01 pivotal trial.
Interim Analysis Timeline: An interim analysis of the trial results is expected by mid-2027.
See More
Bicara Therapeutics Advances Ficerafusp Alfa in Clinical Trials
- Clinical Trial Progress: Bicara Therapeutics has selected 1500mg as the optimal dose in the FORTIFI-HN01 pivotal trial, having initiated Phase 3 with substantial enrollment expected by the end of 2026, thereby laying the groundwork for an interim analysis in mid-2027, indicating significant advancements in treating HPV-negative head and neck cancer.
- Funding Success: The company raised $161.8 million in net proceeds through an oversubscribed public offering, which will be utilized to support regulatory filings and commercialization preparations for ficerafusp alfa, further accelerating its development in 1L R/M HPV-negative head and neck cancer and strengthening its financial position.
- Increased R&D Spending: Research and development expenses reached $33 million in Q4 2025, up from $19.9 million in Q4 2024, primarily due to ongoing pivotal trial costs and rising personnel expenses, reflecting the company's commitment to clinical development.
- Future Milestones: Bicara plans to present long-term follow-up data on ficerafusp alfa at the 2026 ASCO Annual Meeting and aims to complete key commercial hires by the end of 2026 to ensure readiness for potential market launch, demonstrating proactive strategic planning for future growth.
See More
Bicara Therapeutics CEO Sells Stock Options
- Stock Option Exercise: Bicara Therapeutics CEO Claire Mazumdar exercised 8,234 stock options and immediately sold them for approximately $154,000, indicating a focus on liquidity while maintaining direct holdings of 339,392 shares valued at about $6.36 million.
- Ownership Change: Mazumdar's direct ownership decreased by 2.37%, yet she retains an additional 227,873 exercisable options, suggesting optimism about the company's future potential despite the short-term reduction in her ownership percentage.
- Market Context: The transaction occurred between March 4 and 6, 2026, with stock prices fluctuating between $18.25 and $18.47, reflecting a 30.60% increase in share price over the past year, indicating market confidence in its treatment solutions.
- Investor Impact Assessment: This transaction is not significant for investors as it was part of a Rule 10b5-1 trading plan, and with clinical trials progressing well despite a net loss of $138 million, investors must weigh risks against potential returns.
See More
Bicara Therapeutics CEO Sells Shares Amid Strong Stock Performance
- Executive Share Sale: Bicara Therapeutics CEO Claire Mazumdar sold 8,234 common shares between March 4 and 6, 2026, for approximately $154,000 at an average price of $18.74 per share, representing a 2.37% reduction in her direct holdings to 339,392 shares, indicating executive selling at a market high.
- Transaction Context: This sale was part of Mazumdar's Rule 10b5-1 trading plan established in February 2025, designed to avoid insider trading accusations, with all shares held directly, suggesting her continued optimism about the company's future without an urgent need to liquidate.
- Financial Performance: Despite the stock reaching a 52-week high of $20.25, Bicara reported a net loss of $138 million in 2025, significantly up from a $68 million loss in 2024, highlighting soaring research costs and necessitating cautious investor assessment of risks.
- Market Outlook and Investment Advice: While clinical trials for its therapies are progressing well, Bicara has yet to generate sales, requiring investor belief in the potential for federal approval and revenue generation; the current stock price increase presents a good selling opportunity, but holding or buying shares involves weighing potential returns against risks.
See More
Bicara Therapeutics Reports Q4 2025 Financial Results
- Financial Performance: Bicara Therapeutics reported a GAAP EPS of -$0.68 for Q4 2025, indicating challenges in profitability that may impact investor confidence and stock performance.
- Cash Position: As of December 31, 2025, Bicara had cash, cash equivalents, and marketable securities totaling $414.8 million, down from $489.7 million in 2024, reflecting pressure on the company's financial management and liquidity.
- Increased R&D Expenses: Research and development expenses rose to $33.0 million in Q4 2025 from $19.9 million in Q4 2024, primarily due to costs associated with ongoing pivotal Phase 2/3 clinical trials and increased personnel costs, highlighting the company's commitment to advancing its pipeline.
- Capital Raising: Bicara raised $161.8 million in net proceeds through an oversubscribed public offering in Q1 2026, bolstering its financial resources to support future R&D projects and clinical trials.
See More
BICARA THERAPEUTICS INC Reports Q4 Net Loss of $37.4 Million; FY2025 Net Loss Totals $138.0 Million
Financial Performance: Bicarat Therapeutics reported a net loss of $37.4 million for the fourth quarter.
Annual Projection: The company anticipates a net loss of $138.0 million for the fiscal year 2025.
See More
BICARA THERAPEUTICS BEGINS PHASE 3 OF FORTIFI-HN01 KEY TRIAL; INTERIM RESULTS ANTICIPATED BY MID-2027
Phase 3 Initiation: Bicarat Therapeutics has initiated Phase 3 of the Fortifi-HN01 pivotal trial.
Interim Analysis Timeline: An interim analysis of the trial results is expected by mid-2027.
See More
Bicara Therapeutics Advances Ficerafusp Alfa in Clinical Trials
- Clinical Trial Progress: Bicara Therapeutics has selected 1500mg as the optimal dose in the FORTIFI-HN01 pivotal trial, having initiated Phase 3 with substantial enrollment expected by the end of 2026, thereby laying the groundwork for an interim analysis in mid-2027, indicating significant advancements in treating HPV-negative head and neck cancer.
- Funding Success: The company raised $161.8 million in net proceeds through an oversubscribed public offering, which will be utilized to support regulatory filings and commercialization preparations for ficerafusp alfa, further accelerating its development in 1L R/M HPV-negative head and neck cancer and strengthening its financial position.
- Increased R&D Spending: Research and development expenses reached $33 million in Q4 2025, up from $19.9 million in Q4 2024, primarily due to ongoing pivotal trial costs and rising personnel expenses, reflecting the company's commitment to clinical development.
- Future Milestones: Bicara plans to present long-term follow-up data on ficerafusp alfa at the 2026 ASCO Annual Meeting and aims to complete key commercial hires by the end of 2026 to ensure readiness for potential market launch, demonstrating proactive strategic planning for future growth.
See More
Bicara Therapeutics CEO Sells Stock Options
- Stock Option Exercise: Bicara Therapeutics CEO Claire Mazumdar exercised 8,234 stock options and immediately sold them for approximately $154,000, indicating a focus on liquidity while maintaining direct holdings of 339,392 shares valued at about $6.36 million.
- Ownership Change: Mazumdar's direct ownership decreased by 2.37%, yet she retains an additional 227,873 exercisable options, suggesting optimism about the company's future potential despite the short-term reduction in her ownership percentage.
- Market Context: The transaction occurred between March 4 and 6, 2026, with stock prices fluctuating between $18.25 and $18.47, reflecting a 30.60% increase in share price over the past year, indicating market confidence in its treatment solutions.
- Investor Impact Assessment: This transaction is not significant for investors as it was part of a Rule 10b5-1 trading plan, and with clinical trials progressing well despite a net loss of $138 million, investors must weigh risks against potential returns.
See More
Bicara Therapeutics CEO Sells Shares Amid Strong Stock Performance
- Executive Share Sale: Bicara Therapeutics CEO Claire Mazumdar sold 8,234 common shares between March 4 and 6, 2026, for approximately $154,000 at an average price of $18.74 per share, representing a 2.37% reduction in her direct holdings to 339,392 shares, indicating executive selling at a market high.
- Transaction Context: This sale was part of Mazumdar's Rule 10b5-1 trading plan established in February 2025, designed to avoid insider trading accusations, with all shares held directly, suggesting her continued optimism about the company's future without an urgent need to liquidate.
- Financial Performance: Despite the stock reaching a 52-week high of $20.25, Bicara reported a net loss of $138 million in 2025, significantly up from a $68 million loss in 2024, highlighting soaring research costs and necessitating cautious investor assessment of risks.
- Market Outlook and Investment Advice: While clinical trials for its therapies are progressing well, Bicara has yet to generate sales, requiring investor belief in the potential for federal approval and revenue generation; the current stock price increase presents a good selling opportunity, but holding or buying shares involves weighing potential returns against risks.
See More
